FTO and hepatocellular carcinoma: Recent studies have shown that the combination strategy of antigen-capturing nanodrug and FTO inhibitor (FB23-2) showed tremendous potential to drive immune checkpoint blockade (ICB)-based immunotherapy, thereby assisting ICB in preventing distant tumor growth and metastasis after the primary tumor ablation therapy of HCC.